Literature DB >> 6356322

Double-blind placebo-controlled evaluation of one year therapy with sucralfate in healed duodenal ulcer.

M G Moshal, J M Spitaels, G L Manion.   

Abstract

Forty patients with duodenal ulcer, considered healed at endoscopy, were entered in a double-blind trial and treated for up to one year with sucralfate, 500 mg before breakfast, lunch, supper and 1000 mg on retiring, or with placebo. The subjects were interviewed and endoscopy was performed at 0, 3, 6, 9 and 12 months or at any time if pain recurred and they returned to the clinic. On relapse, the patients were withdrawn from trial. The remission rate maintained by sucralfate was superior to that achieved by placebo. The difference was significant (p less than 0.05) at 6 months (64% vs. 27%) and at 12 months (56% vs. 18%). No important side effects were noted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356322

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  3 in total

Review 1.  Drugs for the prevention of peptic ulcer recurrence.

Authors:  D W Piper
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 2.  Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature.

Authors:  A Chines; R Pacifici
Journal:  Calcif Tissue Int       Date:  1990-11       Impact factor: 4.333

Review 3.  Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.